Beyond their symptoms, are chronic rhinosinusitis patients also suffering from a lack of innovation in the ear, nose and throat therapeutic space?
Maryam Mahdi | | Quick Read
For the 65 percent of chronic rhinosinusitis (CRS) patients who experience a relapse of the condition after surgery and require surgical revision, daily medication to manage the symptoms is a reality. CRS affects between one and five percent of the US population and is defined as the inflammation of the nose and paranasal sinuses. The disease can be sub-categorized into two groups; CRS with nasal polyps and CRS without nasal polyps. Even in cases of successful surgery, patients must continue to take medicines.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine